Sharon Shacham
2019
In 2019, Sharon Shacham earned a total compensation of $3M as President and Chief Scientific Officer at Karyopharm Therapeutics, a 45% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $250,648 |
|---|---|
| Option Awards | $1,486,339 |
| Salary | $468,500 |
| Stock Awards | $803,112 |
| Other | $11,860 |
| Total | $3,020,459 |
Shacham received $1.5M in option awards, accounting for 49% of the total pay in 2019.
Shacham also received $250.6K in non-equity incentive plan, $468.5K in salary, $803.1K in stock awards and $11.9K in other compensation.
Rankings
In 2019, Sharon Shacham's compensation ranked 4,058th out of 13,971 executives tracked by ExecPay. In other words, Shacham earned more than 71.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,058 out of 13,971 | 71st |
Division Manufacturing | 1,466 out of 5,698 | 74th |
Major group Chemicals And Allied Products | 514 out of 2,197 | 77th |
Industry group Drugs | 433 out of 1,883 | 77th |
Industry Pharmaceutical Preparations | 330 out of 1,395 | 76th |
Source: SEC filing on April 9, 2020.
Shacham's colleagues
We found three more compensation records of executives who worked with Sharon Shacham at Karyopharm Therapeutics in 2019.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019